Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Breathable Dry Silver/Silver Chloride Electronic Textile Electrodes for Electrodermal Activity Monitoring.

Haddad PA, Servati A, Soltanian S, Ko F, Servati P.

Biosensors (Basel). 2018 Aug 24;8(3). pii: E79. doi: 10.3390/bios8030079.

2.

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial.

Barnes TRE, Leeson V, Paton C, Marston L, Osborn DP, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T.

Ther Adv Psychopharmacol. 2018 Jul;8(7):185-197. doi: 10.1177/2045125318762365. Epub 2018 Mar 8.

3.
4.

Stand-alone cognitive behavioural therapy is not in clinical equipoise with antipsychotic treatment - Author's reply.

Morrison AP, Law H, Shiers D, Yung AR, Haddad PM.

Lancet Psychiatry. 2018 Jul;5(7):540-541. doi: 10.1016/S2215-0366(18)30218-9. No abstract available.

PMID:
29941130
5.

Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.

Morrison AP, Law H, Carter L, Sellers R, Emsley R, Pyle M, French P, Shiers D, Yung AR, Murphy EK, Holden N, Steele A, Bowe SE, Palmier-Claus J, Brooks V, Byrne R, Davies L, Haddad PM.

Lancet Psychiatry. 2018 May;5(5):411-423. doi: 10.1016/S2215-0366(18)30096-8. Epub 2018 Apr 5.

6.

Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980).

Green AR, Haddad PM, Aronson JK.

Br J Clin Pharmacol. 2018 Aug;84(8):1668-1685. doi: 10.1111/bcp.13549. Epub 2018 Mar 25. Review.

PMID:
29442380
7.

Can Video Conferencing Facilitate Better Discharge Processes and a Superior Patient Experience?

Grummet J, Wickramasinghe N, Haddad P, O'Connor L.

Stud Health Technol Inform. 2017;245:1360.

PMID:
29295439
8.

Key Factors for the Successful Adoption of IS/IT in Healthcare: A Fit-Viability Perspective.

Wickramasinghe N, Haddad P, Muhammad I.

Stud Health Technol Inform. 2017;245:1313.

PMID:
29295396
9.

Measuring User Satisfaction with Clinical Information Systems: What Really Matters?

Schaffer JL, Haddad P, Wickramasinghe N.

Stud Health Technol Inform. 2017;245:1311.

PMID:
29295394
10.

Dr Correll and Colleagues Reply.

Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Kane JM.

J Clin Psychiatry. 2017 Sep/Oct;78(8):e1062. doi: 10.4088/JCP.16lr11402a. No abstract available.

11.

Effects of Flexible Dry Electrode Design on Electrodermal Activity Stimulus Response Detection.

Haddad PA, Servati A, Soltanian S, Ko F, Servati P.

IEEE Trans Biomed Eng. 2017 Dec;64(12):2979-2987. doi: 10.1109/TBME.2017.2754220. Epub 2017 Sep 18.

PMID:
28922112
12.

Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.

Barnes TR, Leeson VC, Paton C, Marston L, Davies L, Whittaker W, Osborn D, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T.

Health Technol Assess. 2017 Sep;21(49):1-56. doi: 10.3310/hta21490.

13.

Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study.

Heald A, Pendlebury J, Anderson S, Narayan V, Guy M, Gibson M, Haddad P, Livingston M.

Ann Gen Psychiatry. 2017 Feb 15;16:12. doi: 10.1186/s12991-017-0134-6. eCollection 2017.

14.

The relationship between childhood trauma and adult psychosis in a UK Early Intervention Service: results of a retrospective case note study.

Reeder FD, Husain N, Rhouma A, Haddad PM, Munshi T, Naeem F, Khachatryan D, Chaudhry IB.

Neuropsychiatr Dis Treat. 2017 Feb 8;13:269-273. doi: 10.2147/NDT.S98605. eCollection 2017.

15.

Pilot study of a culturally adapted psychoeducation (CaPE) intervention for bipolar disorder in Pakistan.

Husain MI, Chaudhry IB, Rahman RR, Hamirani MM, Mehmood N, Haddad PM, Hodsoll J, Young AH, Naeem F, Husain N.

Int J Bipolar Disord. 2017 Dec;5(1):3. doi: 10.1186/s40345-017-0074-8. Epub 2017 Feb 11.

16.

Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial.

Husain MI, Chaudhry IB, Hamirani MM, Minhas FA, Kazmi A, Hodsoll J, Haddad PM, Deakin JF, Husain N, Young AH.

Neuropsychiatr Dis Treat. 2016 Dec 19;13:1-8. doi: 10.2147/NDT.S115002. eCollection 2017.

17.

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.

Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM.

J Clin Psychiatry. 2016;77(suppl 3):1-24. doi: 10.4088/JCP.15032su1. Review.

18.

Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability.

Singh SM, Haddad PM, Husain N, Heaney E, Tomenson B, Chaudhry IB.

Ther Adv Psychopharmacol. 2016 Jun;6(3):162-71. doi: 10.1177/2045125316632458. Epub 2016 Mar 10.

19.

Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.

Emsley R, Alptekin K, Azorin JM, Cañas F, Dubois V, Gorwood P, Haddad PM, Naber D, Olivares JM, Papageorgiou G, Roca M, Thomas P, Hargarter L, Schreiner A; EMEA ADHES group.

Ther Adv Psychopharmacol. 2015 Dec;5(6):339-50. doi: 10.1177/2045125315612013.

20.

Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.

McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HC, Haddad PM, Hughes T, Lloyd AJ, Mamasoula C, McColl E, Pearce S, Siddiqi N, Sinha BN, Steen N, Wainwright J, Winter FH, Ferrier IN, Watson S; ADD Study Team.

Lancet Psychiatry. 2016 Feb;3(2):117-27. doi: 10.1016/S2215-0366(15)00436-8. Epub 2015 Dec 23.

PMID:
26727041
21.

In Vitro Assessment of Electric Currents Increasing the Effectiveness of Vancomycin Against Staphylococcus epidermidis Biofilms.

Haddad PA, Mah TF, Mussivand T.

Artif Organs. 2016 Aug;40(8):804-10. doi: 10.1111/aor.12678. Epub 2015 Dec 29.

PMID:
26713750
22.

Diet, exercise and the metabolic syndrome in schizophrenia: A cross-sectional study.

Heald A, Sein K, Anderson S, Pendlebury J, Guy M, Narayan V, Gibson M, Haddad P, Livingston M.

Schizophr Res. 2015 Dec;169(1-3):494-495. doi: 10.1016/j.schres.2015.10.043. Epub 2015 Nov 14. No abstract available.

PMID:
26589389
23.

Managing inadequate antidepressant response in depressive illness.

Haddad PM, Talbot PS, Anderson IM, McAllister-Williams RH.

Br Med Bull. 2015 Sep;115(1):183-201. doi: 10.1093/bmb/ldv034. Epub 2015 Aug 26. Review.

PMID:
26311502
24.

Antipsychotic therapeutic drug monitoring: psychiatrists' attitudes and factors predicting likely future use.

Law S, Haddad PM, Chaudhry IB, Husain N, Drake RJ, Flanagan RJ, David AS, Patel MX.

Ther Adv Psychopharmacol. 2015 Aug;5(4):214-23. doi: 10.1177/2045125315588032.

25.

Glasgow Antipsychotic Side-effects Scale for Clozapine - Development and validation of a clozapine-specific side-effects scale.

Hynes C, Keating D, McWilliams S, Madigan K, Kinsella A, Maidment I, Feetam C, Drake RJ, Haddad PM, Gaughran F, Taylor M, Clarke M.

Schizophr Res. 2015 Oct;168(1-2):505-13. doi: 10.1016/j.schres.2015.07.052. Epub 2015 Aug 12.

PMID:
26276305
26.

Evaluating Business Value of IT in Healthcare: Three Clinical Practices from Australia and the US.

Haddad P, Schaffer JL, Wickramasinghe N.

Stud Health Technol Inform. 2015;216:183-7.

PMID:
26262035
27.

Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study).

Ferrier IN, Anderson IM, Barnes J, Gallagher P, Grunze HCR, Haddad PM, House AO, Hughes T, Lloyd AJ, Mamasoula C, McColl E, Pearce S, Siddiqi N, Sinha B, Speed C, Steen N, Wainwright J, Watson S, Winter FH, McAllister-Williams RH; the ADD Study Team.

Southampton (UK): NIHR Journals Library; 2015 Jun.

28.

Guidance on switching away from Piportil Depot® (pipotiazine palmitate) injection.

Haddad P, Taylor M, Patel MX, Taylor D.

Br J Psychiatry. 2015 Jun;206(6):521. doi: 10.1192/bjp.206.6.521. No abstract available.

PMID:
26034183
29.

Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance.

Haddad PM, Kishimoto T, Correll CU, Kane JM.

Curr Opin Psychiatry. 2015 May;28(3):216-21. doi: 10.1097/YCO.0000000000000160. Review.

PMID:
25785710
30.

A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial.

Chaudhry IB, Husain N, ur Rahman R, Husain MO, Hamirani MM, Kazmi A, Baig S, Haddad PM, Buch MH, Qureshi I, Mehmood N, Kiran T, Fu B, Afsar S, Deakin B.

Trials. 2015 Jan 7;16:9. doi: 10.1186/1745-6215-16-9.

31.

A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.

Das AK, Malik A, Haddad PM.

Ther Adv Psychopharmacol. 2014 Oct;4(5):179-85. doi: 10.1177/2045125314542098.

32.

Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics.

Adam UU, Husain N, Haddad PM, Munshi T, Tariq F, Naeem F, Chaudhry IB.

Neuropsychiatr Dis Treat. 2014 Oct 14;10:1953-9. doi: 10.2147/NDT.S68297. eCollection 2014.

33.

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.

Haddad PM, Brain C, Scott J.

Patient Relat Outcome Meas. 2014 Jun 23;5:43-62. doi: 10.2147/PROM.S42735. eCollection 2014. Review.

34.

SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.

Haddad PM, Fleischhacker WW, Peuskens J, Cavallaro R, Lean ME, Morozova M, Reynolds G, Azorin JM, Thomas P, Möller HJ.

Ther Adv Psychopharmacol. 2014 Feb;4(1):15-21. doi: 10.1177/2045125313510195.

35.

Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.

Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM.

Eur Neuropsychopharmacol. 2014 May;24(5):822-35. doi: 10.1016/j.euroneuro.2013.09.011. Epub 2013 Oct 12. Review.

PMID:
24287012
36.

Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia.

Haddad PM.

Evid Based Ment Health. 2013 Nov;16(4):109. doi: 10.1136/eb-2013-101441. Epub 2013 Oct 3. No abstract available.

PMID:
24091617
37.

Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).

McAllister-Williams RH, Smith E, Anderson IM, Barnes J, Gallagher P, Grunze HC, Haddad PM, House AO, Hughes T, Lloyd AJ, McColl EM, Pearce SH, Siddiqi N, Sinha B, Speed C, Steen IN, Wainright J, Watson S, Winter FH, Ferrier IN.

BMC Psychiatry. 2013 Aug 3;13:205. doi: 10.1186/1471-244X-13-205.

38.

The size, burden and cost of disorders of the brain in the UK.

Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, Joyce E, Rowe J, Wellsted D, Nutt DJ, Sahakian BJ.

J Psychopharmacol. 2013 Sep;27(9):761-70. doi: 10.1177/0269881113495118. Epub 2013 Jul 24.

39.

Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa.

Olivares JM, Alptekin K, Azorin JM, Cañas F, Dubois V, Emsley R, Gorwood P, Haddad PM, Naber D, Papageorgiou G, Roca M, Thomas P, Martinez G, Schreiner A.

Patient Prefer Adherence. 2013;7:121-32. doi: 10.2147/PPA.S37534. Epub 2013 Jan 30.

40.

Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.

Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL.

J Psychopharmacol. 2013 Apr;27(4):358-65. doi: 10.1177/0269881112473789. Epub 2013 Jan 23.

PMID:
23343595
41.

Improving treatment adherence in your patients with schizophrenia: the STAY initiative.

Cañas F, Alptekin K, Azorin JM, Dubois V, Emsley R, García AG, Gorwood P, Haddad PM, Naber D, Olivares JM, Papageorgiou G, Roca M.

Clin Drug Investig. 2013 Feb;33(2):97-107. doi: 10.1007/s40261-012-0047-8. Review.

PMID:
23288695
42.

Bipolar disorder.

Anderson IM, Haddad PM, Scott J.

BMJ. 2012 Dec 27;345:e8508. doi: 10.1136/bmj.e8508. Review. No abstract available.

PMID:
23271744
43.

Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database.

Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL.

J Clin Psychiatry. 2012 Jun;73(6):e749-55. doi: 10.4088/JCP.11m07246.

PMID:
22795214
44.

Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.

Novick D, Haro JM, Bertsch J, Anand H, Jemiai N, Haddad PM.

Int Clin Psychopharmacol. 2012 Sep;27(5):275-82. doi: 10.1097/YIC.0b013e328354db12.

PMID:
22699789
45.

Challenges in the management of early psychosis.

Haddad PM, Chaudhry IB.

J Psychopharmacol. 2012 May;26(5 Suppl):6-7. doi: 10.1177/0269881111405365. No abstract available.

PMID:
22572072
46.

Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.

Haddad PM, Das A, Keyhani S, Chaudhry IB.

J Psychopharmacol. 2012 May;26(5 Suppl):15-26. doi: 10.1177/0269881111424929. Epub 2011 Nov 5. Review.

PMID:
22057019
47.

The place of observational studies in assessing the effectiveness of depot antipsychotics.

Haddad PM, Tiihonen J, Haukka J, Taylor M, Patel MX, Korhonen P.

Schizophr Res. 2011 Sep;131(1-3):260-1. doi: 10.1016/j.schres.2011.05.022. Epub 2011 Jun 12. No abstract available.

PMID:
21665440
48.

Prescribing antidepressants for depression: time to be dimensional and inclusive.

Anderson IM, Haddad PM.

Br J Gen Pract. 2011 Jan;61(582):50-2. doi: 10.3399/bjgp11X548992.

49.

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P.

Am J Psychiatry. 2011 Jun;168(6):603-9. doi: 10.1176/appi.ajp.2011.10081224. Epub 2011 Mar 1. Erratum in: Am J Psychiatry. 2012 Feb;169(2):223.

PMID:
21362741
50.

Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.

Novick D, Haro JM, Bertsch J, Haddad PM.

J Clin Psychopharmacol. 2010 Oct;30(5):531-40. doi: 10.1097/JCP.0b013e3181f14098.

PMID:
20814320

Supplemental Content

Loading ...
Support Center